Premium
Immune regulatory cells in umbilical cord blood: T regulatory cells and mesenchymal stromal cells
Author(s) -
Tolar Jakub,
Hippen Keli L.,
Blazar Bruce R.
Publication year - 2009
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2009.07781.x
Subject(s) - mesenchymal stem cell , umbilical cord , medicine , immune system , immunology , stromal cell , haematopoiesis , bone marrow , graft versus host disease , transplantation , cell therapy , cancer research , stem cell , biology , pathology , microbiology and biotechnology
Summary A major goal in haematopoietic cell transplantation (HCT) is to retain the lymphohaematopoietic potential of the cell transfer without its side effects. In addition to the physical injury caused by the conditioning regimen, donor T cells can react to alloantigens of the recipient and cause graft‐ versus ‐host disease (GVHD), which accounts for the largest share of morbidity and mortality after HCT. Immune modulator cells, such as regulatory T cells (Tregs) and mesenchymal stromal cells (MSCs) have shown promise in their ability to control GVHD and yet, in preclinical models, preserve the graft‐ versus ‐malignancy effect. Initially, MSCs and Tregs have been isolated from adult sources, such as bone marrow or peripheral blood, respectively. More recent studies have indicated that umbilical cord blood (UCB) is a rich source of both cell types. We will review the current data on UCB‐derived Tregs and MSCs and their therapeutic implications.